GlassScriptPhysician profile
Rivka Bortz
NPI 1437708286
$2,776.97
in general payments reported to CMS, 2019-2025
22 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $661 · 2022: $571 · 2023: $758 · 2024: $453 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.78 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $581.37 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $484.36 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $371.65 | 2021-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.44 | 2021-2025 | Jardiance |
| Abbvie INC. | $204.83 | 2021-2024 | |
| Pfizer INC. | $145.33 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $132.11 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $128.18 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $83.01 | 2021-2022 | |
| Eisai INC. | $64.26 | 2021-2022 | |
| Exact Sciences Corporation | $55.58 | 2025 | Cologuard Collection Kit |
| Genzyme Corporation | $37.88 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $31.12 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.57 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $21.53 | 2023 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $20.39 | 2022 | |
| Seqirus USA INC | $20.31 | 2025 | Flucelvax, Fluad |
| Neurocrine Biosciences, INC. | $19.68 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.06 | 2023 | Evkeeza |
| Paratek Pharmaceuticals, INC. | $16.68 | 2025 | Nuzyra |
| Smith+Nephew, INC. | $15.20 | 2023 | Collagenase Santyl |
| Biohaven Pharmaceuticals, INC. | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rivka Bortz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.